Number of clinical trials by country
Annual number of completed clinical trials registered in the ClinicalTrials.gov database for each country. Registration in the ClinicalTrials database is mandatory for trials in the United States, but voluntary for other countries.
Countries reporting
148
Highest
6,222 trials
United States
Lowest
1 trials
Reunion
Median
8 trials
Years covered
25
2000–2024
Data points
2,621
What the numbers show
Number of clinical trials is currently reported for 148 countries. The highest value is 6,222 trials in United States; the lowest is 1 trials in Reunion.
The median across all reporting countries is 8 trials, and the mean is 131.2 trials.
The gap between the highest and lowest reporting country is a factor of about 6,222.
Over the past decade 102 countries rose and 25 fell. The largest increase was in Iraq (up 3,100.0%), and the largest decrease in Panama (down 75.0%).
Number of clinical trials: full country ranking
| # | Country | Latest | Year | 10-year change | Trend |
|---|---|---|---|---|---|
| 1 | United States | 6,222 trials | 2024 | up 19.8% | volatile |
| 2 | Turkey | 2,075 trials | 2024 | up 2,039.2% | volatile |
| 3 | China | 1,649 trials | 2024 | up 308.2% | volatile |
| 4 | Egypt | 1,144 trials | 2024 | up 1,405.3% | volatile |
| 5 | France | 896 trials | 2024 | up 42.2% | volatile |
| 6 | Spain | 566 trials | 2024 | up 125.5% | volatile |
| 7 | Italy | 561 trials | 2024 | up 119.1% | volatile |
| 8 | Canada | 527 trials | 2024 | unchanged | volatile |
| 9 | United Kingdom | 487 trials | 2024 | up 2.1% | volatile |
| 10 | Pakistan | 452 trials | 2024 | up 2,558.8% | volatile |
| 11 | Germany | 420 trials | 2024 | down 24.7% | volatile |
| 12 | South Korea | 282 trials | 2024 | down 39.2% | volatile |
| 13 | Denmark | 258 trials | 2024 | up 0.8% | volatile |
| 14 | Netherlands | 251 trials | 2024 | up 8.2% | volatile |
| 15 | Taiwan | 235 trials | 2024 | up 104.3% | volatile |
| 16 | Switzerland | 231 trials | 2024 | up 63.8% | volatile |
| 17 | Belgium | 205 trials | 2024 | up 3.5% | volatile |
| 18 | Brazil | 163 trials | 2024 | down 14.7% | volatile |
| 19 | Sweden | 162 trials | 2024 | up 20.9% | volatile |
| 20 | Australia | 158 trials | 2024 | up 62.9% | volatile |
| 21 | Japan | 138 trials | 2024 | down 44.6% | volatile |
| 22 | India | 131 trials | 2024 | up 20.2% | volatile |
| 23 | Poland | 121 trials | 2024 | up 116.1% | volatile |
| 24 | Hong Kong | 112 trials | 2024 | up 433.3% | volatile |
| 25 | Thailand | 105 trials | 2024 | up 54.4% | volatile |
| 26 | Russia | 96 trials | 2024 | up 84.6% | volatile |
| 27 | Indonesia | 88 trials | 2024 | up 363.2% | volatile |
| 28 | Austria | 86 trials | 2024 | up 8.9% | volatile |
| 29 | Norway | 85 trials | 2024 | down 18.3% | volatile |
| 30 | Greece | 72 trials | 2024 | up 33.3% | volatile |
| 31 | Mexico | 68 trials | 2024 | up 21.4% | volatile |
| 32 | Israel | 64 trials | 2024 | down 42.9% | volatile |
| 33 | Saudi Arabia | 58 trials | 2024 | up 286.7% | volatile |
| 33 | Vietnam | 58 trials | 2024 | up 383.3% | volatile |
| 35 | Singapore | 57 trials | 2024 | up 14.0% | volatile |
| 36 | Portugal | 56 trials | 2024 | up 229.4% | volatile |
| 37 | South Africa | 54 trials | 2024 | up 68.8% | volatile |
| 38 | Finland | 51 trials | 2024 | down 3.8% | volatile |
| 39 | Czechia | 50 trials | 2024 | up 78.6% | volatile |
| 40 | Malaysia | 44 trials | 2024 | up 91.3% | volatile |
| 41 | Chile | 43 trials | 2024 | up 290.9% | volatile |
| 42 | Slovenia | 35 trials | 2024 | up 84.2% | volatile |
| 43 | Colombia | 33 trials | 2024 | up 153.8% | volatile |
| 44 | Iraq | 32 trials | 2024 | up 3,100.0% | volatile |
| 44 | Kenya | 32 trials | 2024 | up 14.3% | volatile |
| 46 | Iran | 31 trials | 2024 | down 20.5% | rising |
| 46 | Nepal | 31 trials | 2024 | up 933.3% | volatile |
| 48 | Hungary | 28 trials | 2024 | up 75.0% | volatile |
| 48 | Uganda | 28 trials | 2024 | up 55.6% | volatile |
| 50 | Argentina | 23 trials | 2024 | down 4.2% | volatile |
| 50 | Jordan | 23 trials | 2024 | up 187.5% | volatile |
| 50 | Romania | 23 trials | 2024 | up 109.1% | volatile |
| 53 | United Arab Emirates | 22 trials | 2024 | up 2,100.0% | volatile |
| 55 | Bangladesh | 20 trials | 2024 | up 11.1% | volatile |
| 55 | New Zealand | 20 trials | 2024 | up 53.8% | volatile |
| 55 | Serbia | 20 trials | 2024 | up 400.0% | volatile |
| 58 | Lebanon | 19 trials | 2024 | up 171.4% | volatile |
| 58 | Philippines | 19 trials | 2024 | up 58.3% | volatile |
| 58 | Tunisia | 19 trials | 2024 | up 58.3% | volatile |
| 61 | Bulgaria | 16 trials | 2024 | up 23.1% | volatile |
| 62 | Syria | 15 trials | 2024 | up 1,400.0% | volatile |
| 63 | Burkina Faso | 13 trials | 2024 | up 62.5% | volatile |
| 63 | Kazakhstan | 13 trials | 2024 | up 550.0% | volatile |
| 63 | Nigeria | 13 trials | 2024 | up 550.0% | volatile |
| 66 | Ethiopia | 12 trials | 2024 | up 100.0% | volatile |
| 66 | Tanzania | 12 trials | 2024 | up 33.3% | volatile |
| 68 | Croatia | 11 trials | 2024 | up 83.3% | volatile |
| 68 | Malawi | 11 trials | 2024 | up 22.2% | volatile |
| 70 | Ghana | 9 trials | 2024 | up 125.0% | volatile |
| 70 | Qatar | 9 trials | 2024 | up 125.0% | volatile |
| 70 | Rwanda | 9 trials | 2024 | up 50.0% | volatile |
| 70 | Ukraine | 9 trials | 2024 | up 80.0% | volatile |
| 70 | Zambia | 9 trials | 2024 | down 10.0% | volatile |
| 75 | Democratic Republic of Congo | 8 trials | 2024 | up 166.7% | volatile |
| 75 | Cyprus | 8 trials | 2024 | up 300.0% | volatile |
| 75 | Kuwait | 8 trials | 2024 | up 700.0% | volatile |
| 75 | Slovakia | 8 trials | 2024 | up 300.0% | rising |
| 79 | Bosnia and Herzegovina | 7 trials | 2024 | up 250.0% | volatile |
| 79 | Cameroon | 7 trials | 2024 | up 250.0% | volatile |
| 79 | Mali | 7 trials | 2024 | up 75.0% | volatile |
| 79 | Peru | 7 trials | 2024 | up 75.0% | rising |
| 79 | Palestine | 7 trials | 2024 | up 600.0% | volatile |
| 84 | Iceland | 6 trials | 2024 | up 200.0% | volatile |
| 85 | Estonia | 5 trials | 2024 | up 25.0% | volatile |
| 85 | Georgia | 5 trials | 2024 | up 150.0% | volatile |
| 85 | Lithuania | 5 trials | 2024 | up 150.0% | volatile |
| 85 | Latvia | 5 trials | 2024 | up 25.0% | volatile |
| 85 | Morocco | 5 trials | 2024 | up 150.0% | volatile |
| 85 | Oman | 5 trials | 2024 | up 400.0% | rising |
| 85 | Sudan | 5 trials | 2024 | up 150.0% | rising |
| 92 | Cambodia | 4 trials | 2024 | unchanged | volatile |
| 92 | Mozambique | 4 trials | 2024 | unchanged | volatile |
| 92 | El Salvador | 4 trials | 2023 | up 300.0% | volatile |
| 95 | Armenia | 3 trials | 2024 | up 200.0% | volatile |
| 95 | Cote d'Ivoire | 3 trials | 2024 | unchanged | volatile |
| 95 | Costa Rica | 3 trials | 2024 | up 200.0% | volatile |
| 95 | Ecuador | 3 trials | 2024 | up 50.0% | volatile |
| 95 | Gambia | 3 trials | 2022 | up 200.0% | volatile |
| 95 | Guatemala | 3 trials | 2024 | up 200.0% | volatile |
| 95 | Kyrgyzstan | 3 trials | 2023 | up 200.0% | volatile |
| 95 | Laos | 3 trials | 2024 | up 50.0% | flat |
| 95 | Lesotho | 3 trials | 2024 | unchanged | rising |
| 95 | Papua New Guinea | 3 trials | 2024 | up 200.0% | rising |
| 95 | Puerto Rico | 3 trials | 2024 | unchanged | rising |
| 95 | Paraguay | 3 trials | 2024 | up 50.0% | rising |
| 108 | Afghanistan | 2 trials | 2022 | up 100.0% | flat |
| 108 | Azerbaijan | 2 trials | 2022 | up 100.0% | rising |
| 108 | Bahrain | 2 trials | 2024 | up 100.0% | volatile |
| 108 | Belarus | 2 trials | 2023 | down 33.3% | volatile |
| 108 | Guinea | 2 trials | 2023 | unchanged | rising |
| 108 | Honduras | 2 trials | 2024 | up 100.0% | volatile |
| 108 | Liberia | 2 trials | 2023 | up 100.0% | rising |
| 108 | Moldova | 2 trials | 2024 | unchanged | volatile |
| 108 | North Macedonia | 2 trials | 2023 | up 100.0% | rising |
| 108 | Myanmar | 2 trials | 2024 | unchanged | volatile |
| 108 | Mongolia | 2 trials | 2024 | up 100.0% | rising |
| 108 | Mauritius | 2 trials | 2023 | up 100.0% | volatile |
| 108 | Niger | 2 trials | 2024 | down 33.3% | rising |
| 108 | Nicaragua | 2 trials | 2024 | up 100.0% | rising |
| 108 | Sierra Leone | 2 trials | 2024 | unchanged | volatile |
| 108 | Trinidad and Tobago | 2 trials | 2023 | up 100.0% | rising |
| 108 | Uruguay | 2 trials | 2023 | up 100.0% | flat |
| 108 | Venezuela | 2 trials | 2024 | up 100.0% | volatile |
| 108 | Zimbabwe | 2 trials | 2024 | up 100.0% | volatile |
| 127 | Albania | 1 trials | 2024 | unchanged | falling |
| 127 | Burundi | 1 trials | 2022 | unchanged | volatile |
| 127 | Benin | 1 trials | 2023 | down 50.0% | rising |
| 127 | Bolivia | 1 trials | 2024 | down 50.0% | volatile |
| 127 | Botswana | 1 trials | 2024 | down 66.7% | volatile |
| 127 | Congo | 1 trials | 2021 | down 50.0% | volatile |
| 127 | Cuba | 1 trials | 2024 | unchanged | volatile |
| 127 | Dominican Republic | 1 trials | 2024 | down 66.7% | volatile |
| 127 | Algeria | 1 trials | 2024 | unchanged | rising |
| 127 | Fiji | 1 trials | 2024 | unchanged | falling |
| 127 | Gabon | 1 trials | 2024 | down 50.0% | rising |
| 127 | Guinea-Bissau | 1 trials | 2024 | down 50.0% | rising |
| 127 | Haiti | 1 trials | 2024 | unchanged | volatile |
| 127 | Jamaica | 1 trials | 2022 | down 50.0% | falling |
| 127 | Sri Lanka | 1 trials | 2024 | down 50.0% | volatile |
| 127 | Monaco | 1 trials | 2024 | down 50.0% | volatile |
| 127 | Madagascar | 1 trials | 2024 | unchanged | falling |
| 127 | Panama | 1 trials | 2024 | down 75.0% | volatile |
| 127 | Senegal | 1 trials | 2024 | down 66.7% | volatile |
| 127 | Eswatini | 1 trials | 2024 | unchanged | falling |
| 127 | Chad | 1 trials | 2022 | unchanged | flat |
| 127 | Uzbekistan | 1 trials | 2024 | unchanged | flat |
| 127 | French Guiana | 1 trials | 2024 | unchanged | volatile |
| 127 | Reunion | 1 trials | 2024 | down 50.0% | volatile |
About this data
Annual number of completed clinical trials registered in the ClinicalTrials.gov database for each country. Registration in the ClinicalTrials database is mandatory for trials in the United States, but voluntary for other countries.